Table 1.
Doubling times of mutants and clinical isolates relating to PAT1646 with or without nitrofurantoin
| Strains | Nitrofurantoin concentration (mg/L)a,b | |||||||
|---|---|---|---|---|---|---|---|---|
| 0 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | |
| 1646 BASE | 21.9 ± 0.9 | 24.7 ± 0.7 | 29.3 ± 1.1 | 43.2 ± 1.8 | ||||
| 1646 6 | 25.7 ± 1.1 | 25.1 ± 0.6 | 24.5 ± 1.2 | 25.3 ± 1.1 | 27.9 ± 0.9 | 35.2 ± 1 | 142 ± 11.3 | |
| 1646B ΔnfsA | 24.2 ± 0.6 | 24.3 ± 0.9 | 23.6 ± 1 | 31 ± 2 | 60.1 ± 1.6 | |||
| 1646B ΔnfsA-rimK | 23.7 ± 0.9 | 26.2 ± 1 | 25.4 ± 1.3 | 32.2 ± 1.9 | 64.7 ± 2.4 | |||
| 1646B nfsA T37M | 22.5 ± 0.8 | 24.2 ± 0.9 | 24.1 ± 1 | 30.3 ± 2.1 | 55.4 ± 2.2 | |||
| 1646B ΔrimK | 24.1 ± 1.2 | 25.3 ± 0.4 | 28.3 ± 1.3 | 45.9 ± 1.4 | ||||
| 1646B ΔnfsB | 22.2 ± 1.1 | 25.9 ± 0.8 | 29.6 ± 1 | 45 ± 0.9 | ||||
| 1646B ΔrimK ΔnfsB | 21.8 ± 1.8 | 25.3 ± 1.2 | 30.5 ± 0.8 | 43.7 ± 1.6 | ||||
| 1646B ΔnfsA ΔnfsB | 25.7 ± 0.4 | 25.6 ± 0.9 | 25 ± 0.5 | 24.3 ± 1 | 26.6 ± 0.3 | 34.2 ± 1.3 | 90.5 ± 5.9 | |
| 1646B ΔnfsA-rimK ΔnfsB | 21.9 ± 1.6 | 23.4 ± 0.8 | 22.6 ± 0.7 | 23.4 ± 1.3 | 27.7 ± 0.9 | 33.7 ± 0.8 | 88 ± 3.4 | |
| 1646B nfsA T37M ΔnfsB | 24.2 ± 0.8 | 25 ± 1.1 | 24.7 ± 0.5 | 27.7 ± 1 | 28.7 ± 0.5 | 37.6 ± 0.9 | 131.6 ± 10.8 | |
Italics and bold identify significant changes in the doubling time (Table S3).
Data relate to growth, while the MIC is defined as the first concentration having an OD600 < 0.05.